Drugs / V180
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02450838 | Apr → Oct 2015 | dengue disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT01477580 | Jul 2012 → Jan 2014 | dengue disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V180 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01477580 ↗ |
| Modality | Vaccine | “The V180 vaccine candidate consists of four recombinant, soluble, dengue virus envelope glycoproteins” PMID 32394880 ↗ May 2020 |
| Route | Intramuscular | “Three 0.5-mL intramuscular doses of low-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2” NCT01477580 ↗ |